Intravenous immunoglobulin (IVIg) therapy has multiple mechanisms of immunomodulatory action. We wished therefore to assess its efficacy in a spectrum of patients with refractory uveitis. Retrospective review of clinical charts was conducted to document response to IVIg treatment in consecutive patients with treatment-refractory uveitis. Main outcome measures were control of intraocular inflammation, visual acuity, progression of the disease, and complications. Four (two male) patients, with a mean age at the beginning of the treatment of 47 years (range: 39–64), were included in the study. Indication for treatment was patients with active non-infectious uveitis refractory to steroids and immunomodulatory therapy. All patients received a course of 0.5 g/kg per day of IVIg for three consecutive days, repeating this course at a mean of 11 week (range: 2–39 weeks) intervals when indicated clinically. The median duration of the IVIg therapy was 7 months (range: 3–14 months). In three patients treatment resulted in stabilisation and prevention of progression of the disease, and additionally in two patients it facilitated a decrease in prednisolone dose. Treatment failed to induce long-term remission in one patient with recurrence of macular oedema. IVIg was well tolerated with neither immediate nor longer-term adverse events observed. In three out of four cases IVIg was an effective adjunctive therapy and well tolerated for the management of treatment-refractory uveitis.
This is a preview of subscription content, log in to check access.
This work was partly supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. All the patients involved in this study have consented to the submission of this case series to the journal.
Salama A, Mueller-Eckhardt C, Kiefel V (1983) Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet 2(8343):193–195CrossRefPubMedGoogle Scholar
Svetlicky N, Blank M, Zandman-Goddard G (2012) The beneficial effects of intravenous immunoglobulin for antineutrophil cytoplasmic antibody-positive vasculitis. Isr Med Assoc J 14(9):568–569PubMedGoogle Scholar
LeHoang P, Cassoux N, George F, Kullmann N, Kazatchkine MD (2000) Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. Ocular Immunol Inflamm 8(1):49–57CrossRefGoogle Scholar
Rosenbaum JT, George RK, Gordon C (1999) The treatment of refractory uveitis with intravenous immunoglobulin. Am J Ophthalmol 127(5):545–549CrossRefPubMedGoogle Scholar
Guy J, Aptsiauri N (1999) Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Arch Ophthalmol 117(4):471–477CrossRefPubMedGoogle Scholar
Dan D, Fischer R, Adler S, Forger F, Villiger PM (2014) Cyclophosphamide: as bad as its reputation? Long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases. Swiss Med Wkly 144:w14030. doi:10.4414/smw.2014.14030PubMedGoogle Scholar